Analytical performance of serum free light-chain assay during monitoring of patients with monoclonal light-chain diseases.

@article{Tate2007AnalyticalPO,
  title={Analytical performance of serum free light-chain assay during monitoring of patients with monoclonal light-chain diseases.},
  author={Jillian Russyll Tate and Peter N. Mollee and Goce Dimeski and Andrew C Carter and Devinder S Gill},
  journal={Clinica chimica acta; international journal of clinical chemistry},
  year={2007},
  volume={376 1-2},
  pages={30-6}
}
BACKGROUND Measurement of serum free light chains (FLC) is useful for the diagnosis and monitoring of monoclonal light-chain diseases. It has been suggested that there will be widespread replacement of urine Bence Jones protein measurement by serum FLC assay. We report on our experience with the assay during monitoring of light-chain myeloma (LCMM) and AL amyloidosis (AL). METHODS Serum FLC immunoassay, serum and/or urine protein electrophoresis and immunofixation were performed on serial… CONTINUE READING